Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Approves Meloxicam Injection & OTC Diclofenac Sodium Topical Gel for Pain Management

  |  Issue: May 2020  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Baudax Bio Inc. News release: Baudax Bio announces FDA approval of Anjeso for the management of moderate to severe pain. 2020 Feb 20.
  2. U.S. Food and Drug Administration. News release: FDA approves three drugs for nonprescription use through Rx-to OTC switch process. 2020 Feb 14.
  3. GlaxoSmithKline. News release: FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the U.S. 2020 Feb 17.

Related Articles
    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

    Pain Treatments Move Closer to U.S. Market

    Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…